Background: Recent research has shown that genetic variation in the IL28B gene predicts both chronicity of HCV infection and sustained virological response (SVR) to antiviral standard therapy. Because HCV affects 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma, screening for prognostic factors in routine clinical practice requires rapid and reliable assays. Methods: The frequencies of gene polymorphisms IL28B rs8099917, rs12979860 and rs12980275 were investigated in two cohorts of 89 and 187 unrelated HCVinfected Caucasian patients and 195 non-infected participants. This was carried out by means of newly developed sensitive Pyrosequencing™ screening assays. Results: The minor alleles were more frequent in patients (n=276) than in controls (n=195), with odds ratios (recessive hereditary model) of 2.2-11.6, indicating a moderate to large genotype effect size. The positive predictive values of the minor alleles for chronicity of HCV infection were 68.3%, 64.8% and 65.8% for rs8099917, rs12979860 and rs12980275, respectively. The minor alleles were also more frequent in patients who had a non-SVR (n=49) than in SVR patients (n=40), with odds ratios of 1.1-3.5 showing a small to moderate genotype effect size. The positive predictive values for non-SVR were 56.9%, 79.2% and 74% for rs8099917, rs12979860 and rs12980275, respectively. Conclusions: With the screening for IL28B polymorphisms rs12980275, rs8099917 and rs12979860, which are associated with HCV chronicity and with reduced SVR rates, an important prognostic factor of the therapy of chronic hepatitis C can be easily diagnosed.
HCV infection affects 170 million individuals worldwide. Patients with chronic hepatitis C (CHC) are at high risk of progressing to liver cirrhosis and its associated complications, including hepatocellular carcinoma [1] . The current therapy consists of a combination of pegylated interferon (IFN)-α with ribavirin [1, 2] . Response to antiviral therapy strongly depends on the HCV genotype. In HCV genotype-1 infection, the most common HCV genotype in Caucasians, therapy leads to a sustained virological response (SVR) in <50% of patients. The therapy is usually administered for 48 weeks [1] and might be prolonged to 72 weeks in selected patients according to the on-treatment antiviral response. IFN-α-based antiviral therapy is characterized by many side effects, such as haemolytic anaemia, influenza-like symptoms or neuropsychiatric symptoms that are, to a variable extent, present in most of the patients [3] . Considering different antiviral response rates and side effects, personalized treatment schedules with variable dosing and durations are highly desirable.
Recently, single nucleotide polymorphisms (SNPs) localized near the IL28B gene, encoding IFN-λ3, (for example, rs8099917 [4, 5] , rs12979860 [6] and rs12980275 [5] ), have been repeatedly [7] shown to be associated with antiviral treatment response, spontaneous clearance of HCV (rs12979860 [8] ) and progression to CHC (rs8099917 [9] ). These polymorphisms might therefore serve as important factors to personalize antiviral therapy of patients with CHC. Reproduction of genetic results in various clinical settings is, however, a prerequisite of establishing such therapy regimens and was, therefore, performed in the present investigation. 
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Introduction Methods
The assays were developed in DNA samples from a healthy, unrelated control group consisting of 97 women and 98 men, aged 18-57 years (mean ±sd 28.4 ±6.1 years), who were mainly medical students at the Goethe-University of Frankfurt (Germany). Patients with CHC genotype-1 were identified from two independent treatment cohorts. The patients of cohort 1 (45 men and 44 women, aged 23-76 years) were treated with standard doses of pegylated IFN-α and weightbased doses of ribavirin for a maximum of 48 weeks at the hepatological outpatient clinic of the GoetheUniversity Hospital in Frankfurt (Germany). A total of 40 patients achieved an SVR (no HCV RNA detectable 24 weeks after completion of treatment) and 49 individuals were classified as non-SVR patients (those who had a <2 log 10 copies/ml HCV RNA reduction by week 12, or had a relapse of HCV RNA after cessation of the 48-week treatment course). The patients of cohort 2 (109 men and 88 women, aged 22-72 years) were treated with pegylated IFN-α2b 1.5 µg/kg body weight and ribavirin 800-1,400 mg/day according to body weight in a multicentre study at different German sites. The latter study is ongoing and data about therapy success is not available. The ethnicity of all participants by self-assignment was Caucasian. Ethics approval and the participants' consent had been obtained.
Genotyping
Genomic DNA was extracted from 200 µl of blood on a BioRobot EZ1 workstation (Qiagen, Hilden, Germany), using the blood and body fluid spin protocol provided in the EZ1 DNA Blood 200 µl Kit (Qiagen). PCR primers for amplification of IL28B gene segments and sequencing primers were designed using the PyroMark Assay Design 2.0 software (version 2.0.1.15; Qiagen). Specificity of primers was verified by alignment. PCR reactions were carried out in a 50 µl assay volume on a Mastercycler ep gradient S instrument (Eppendorf, Hamburg, Germany), using 5 µl genomic DNA (20-30 µg/ml), mixed with 0.25 µl HotStarTaq plus DNA polymerase (5 U/µl; Qiagen), 5 µl 10×PCR buffer, 10 µl 5× Q-Solution, 1 µl of deoxynucleoside triphosphate mix (10 mmol/l each; Qiagen), 0.1 µl of one biotinylated and one non-biotinylated PCR primer (each 100 µmol/l; rs8099917A>C forward primer 5′-TCATCCCACTTCTGGAACAAA-3′, reverse primer 5′-biotin-TGGGAGAATGCAAA TGAGAGATAA-3′; rs12979860G>A forward primer 5′-ATTCCTGGACGTGGATGGGTACT-3′, reverse primer 5′-biotin-GGAGCGCGGAGTGCAATT-3′; rs12980275T>C forward primer 5′-GTCAGTGAAA TAAGCCAGTCTCAA-3′, reverse primer 5′-biotin-TACATTGTTCGGCAAGCAATCT-3′) and 28.55 µl HPLC-purified water. The PCR was carried out with an initial denaturation step for 5 min at 95°C, 45 cycles with a 30 s denaturation step at 95°C, an annealing step at 60°C (rs8099917 and rs12980275) or 64°C (rs12979860) for 30 s and an elongation step at 72°C for 30 s, followed by a final elongation step at 72°C for 5 min. After PCR amplification, several samples were evaluated by capillary electrophoresis on a QIAxcel instrument (Qiagen); the sizes of the PCR products were 316 base pairs for rs8099917A>C, 108 base pairs for rs12979860G>A and 210 base pairs for rs12980275T>C. For rs8099917A>C, to sustain the conventional gene description from the 5′-end to 3′-end, we changed the SNP denomination in comparison to previous publications [4] [5] [6] 7.6 ) and 15 µl HPLC-purified water. This mixture was incubated for 10 min at room temperature (shaker speed 800 shakes/min) to form specific complexes between streptavidin-coated Sepharose beads and biotinylated strands. The complexes were purified and separated from the non-biotinylated strands on a PyroMark Vacuum Prep Worktable (Biotage, Uppsala, Sweden); by suction, the specific complexes were captured on PrepTool filters (Biotage), purified into 70% ethanol for 5 s, denatured in 0.2 mol/l NaOH for 5 s and washed with Tris(hydroxymethyl)-aminomethan (10 mmol/l in water) for 5 s. The complexes were then transferred to a PSQ 96 Plate Low (Biotage) pre-filled with 0.16 µl of 100 µmol/l sequencing primer (for rs8099917A>C 5′-TTTTCCTTTCTGTGAGC-3′; for rs12979860G>A 5′-AGCTCCCCGAAGGCG-3′; and for rs12980275T>C 5′-GAAGTCAAATTCCTA GAAAC-3′) and 39.84 µl annealing buffer (20 mmol/l Tris[hydroxymethyl]-aminomethan and 2 mmol/l magnesium acetate tetrahydrate; pH 7.6). Subsequently, the plate was heated at 80°C for exactly 2 min in a PSQ 96 Sample Prep Thermoplate Low (Biotage) and cooled down to room temperature. Sequencing analysis [29] [30] [31] , an oligonucleotide (sequencing primer) binds to purified single-stranded DNA close to the mutation site and is elongated by specific dispensing of deoxynucleoside triphosphates (dNTPs). If the dispensed dNTP matches the next nucleotide of the DNA, it is incorporated into the oligonucleotide and pyrophosphate is released. The pyrophosphate, together with adenosine-5-phosphosulfate, is converted to ATP, which triggers a luciferase-catalysed luciferin-to-oxyluciferin conversion. The resulting light is shown as a peak with a height proportional to the number of incorporated nucleotides in the so-called pyrograms. The relevant positions for genotype identification are framed with dashed lines. The genetic diagnosis is obtained automatically by the software controlling the Pyrosequencing™ device; thus, the pyrograms need not be read by the researcher. The DNA sequence on the forward DNA strand following the sequencing primer accords to the sequence to be analysed and determines the nucleotide dispensation order. The pyrograms denote the three possible genotypes for each DNA position. Note that the initial part in the pyrograms corresponding to the dispensation of enzyme and substrate mixes has been omitted. From conventional IL28B sequencing, only the fragments relevant for identifying the single nucleotide polymorphisms (SNPs; framed with solid lines) are displayed (different style lines code for the nucleotides). Although the variant DNA loci for rs12979860 and rs12980275 are diagnosed by automatic reading of two peaks, which symbolizes the presence of two copies of either nucleotide of the SNP or of one copy of both possible nucleotides, rs8099917 is diagnosed from three peaks. The explanation lies in the particular sequence of the DNA of TCGTTA, followed by adenine or cytosine, and then by AGTGGGTTT. In the wild-type genotype, this sequence is TCGTTAAAGTGGGTTT, which produces the triple high adenine peak (bold 'A's). In the variant genotype, the sequence is TCGTTACAGTGGGTTT, which produces three peaks (A, C and A) because the adenine after the SNP is separated and does not add to the adenine before the SNP, as in the wild type. Because of the identity of the positions before and after the SNP, together with a further identical nucleotide in the SNP, its diagnosis involves three pyrogram peaks rather than the usual two.
( Figure 1 ) took place on a PSQ 96 MA System (Biotage) with a Biotage enzyme mix, a substrate mix and nucleotides (Pyro Gold Reagents set for SNP genotyping and mutation analysis). For all assays, two samples of each genotype were selected, sequenced by conventional means (AGOWA GmbH, Berlin, Germany) and used as positive controls during Pyrosequencing™.
Statistical analyses
The correspondence between the observed number of homozygous and heterozygous individuals and the numbers statistically expected from the Hardy-Weinberg equilibrium [10] were assessed by χ 2 goodness-of-fit tests separately for both patient cohorts and controls. Haploblock organization was analysed with the 95% confidence intervals on the measure of linkage, calculated as the probability of joint observation of the variants minus the product of the probabilities of the constituent alleles, normalized to the theoretical maximum linkage of the observed allele frequencies (D′) approach [11] (SVS software version 7.2.2; Golden Helix, Bozeman, MT, USA), which identifies haploblocks of two or three SNPs on the basis of their linkages. Linkage disequilibrium (LD) was additionally quantified by calculating r 2 [12, 13] . k statistics [14] were applied to assess whether the diagnosis of one SNP could also provide that of the others, which could simplify the laboratory [15] . χ 2 statistics were applied to compare each patient cohort and controls with respect to allele counts (basic allele test), the number of carriers of the minor alleles of each SNP versus non-carriers (dominant model) and the number of homozygous carriers of the minor alleles versus pooled heterozygous and non-carriers (recessive model). In addition, within patient cohort 1, the association of IL28B polymorphisms with therapy success was analysed by comparing the minor allele frequency between therapy responders and non-responders, using 
Results
Identification of the three IL28B variants by the Pyrosequencing TM assays agreed with the positive controls ( Figure 1 ). Genotype distributions followed the Hardy-Weinberg law (χ 2 -tests P≥0.1 for all three cohorts and IL28B variants). Linkage among the three SNPs was high with values of D′≥0.92 and of r 2 ≥0.42; however, no haploblock was identified. The agreement between the three SNPs was nevertheless already substantial as indicated by a value of k=0.61. Because pairwise k-values were only 0.49 for Although the minor alleles were similarly frequent in both patient cohorts (P≥0.46), they were significantly more frequent in patients with CHC than in healthy controls ( Table 1 ). The genotype effects on the disease risk were large when applying the recessive hereditary model to rs8099917, which resulted in odds ratios of 11.55 (95% confidence interval [CI] 1.33-100.36) or 9.81 (95% CI 1.23-78.20) for patient cohorts 1 and 2, respectively. Therapy success information, available only from cohort 1, showed that non-SVR patients carried the minor C or 'non-responder' [16] allele of rs8099917 (odds ratio 2.2, 95% CI 1.09-4.43; P=0.026) more often than patients who achieved an SVR. Significance was best with the dominant model and basic allele test (Tables 2, 3 and 4). The PPV of the minor alleles for poor therapy response were 56.9%, 79.2% and 74% for rs8099917 C, rs12979860 A and rs12980275 C, (because of the different direction of DNA reading, the minor alleles might be complementary in other publications, that is, rs8099917 G, rs12979860 T and rs12980275 G), respectively. The PPVs of the homozygous presence of the respective minor allele's predictive values were 40%, 92.3% and 85.7%.
Discussion
Recently reported associations of the three IL28B variants with hepatitis C chronicity and therapy outcome have raised hopes that they could be used for clinical decisions on dosing and duration of IFN- b Patients treated with pegylated IFN-α2b 1.5 µg/kg body weight and ribavirin 800-1,400 mg/day according to body weight.
c Please note that to sustain the conventional gene description from the 5′-end to 3′-end, the single nucleotide polymorphism (SNP) denominations were changed from previous publications [4] [5] [6] , that is, rs8099917A>C might be elsewhere named T>G, rs12979860G>A might be named C>T and rs12980275T>C is also named A>G. CI, confidence interval.
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Mean b Please note that to sustain the conventional gene description from the 5′-end to 3′-end, the single nucleotide polymorphism (SNP) denominations were changed from previous publications [4] [5] [6] , that is, rs8099917A>C might be elsewhere named T>G, rs12979860G>A might be named C>T and rs12980275T>C is also named A>G. CI, confidence interval. Table 3 . Results of statistical group comparisons applying different statistical models of inheritance in patient cohort 2 a versus controls a Patients treated with pegylated IFN-α2b 1.5 µg/kg body weight and ribavirin 800-1,400 mg/day according to body weight. b Please note that to sustain the conventional gene description from the 5′-end to 3′-end, the single nucleotide polymorphism (SNP) denominations were changed from previous publications [4] [5] [6] , that is, rs8099917A>C might be elsewhere named T>G, rs12979860G>A might be named C>T and rs12980275T>C is also named A>G. CI, confidence interval. based antiviral therapy, and might, therefore, represent a major step towards personalized medicine [17] . With odds ratios between 1.6 and 2.2 (basic allele tests), the effects of IL28B variants on hepatitis C treatment failure (non-SVR) are small to moderate; thus, the gene product of IL28B is probably a modulating factor on the course of HCV infection towards eradication or, alternatively, persistence. Theoretically, the present data would even allow a hypothesis that states that IL28B SNPs could represent a risk factor for HCV infection acquisition; however, possible selection bias of the present cohorts requires independent verification. IL28A (IFN-λ2), IL28B (IFN-λ3) and IL29 (IFN-λ1) bind to a heterodimeric receptor consisting of IL10Rβ and IL28Rα. The heterodimerization results in activation of the Janus kinase signal transducer and activator of transcription and the mitogen-activated protein kinase signal transduction pathways and a gene expression pattern similar to that of type-I IFNs (IFN-α and IFN-β) [18] . In vitro and in vivo models have shown the importance of IFN-λs in the immune response to several viruses, including herpes simplex virus, encephalomyocarditis virus and HBV [19] . Various studies with human hepatic cell lines showed an IFN-λ-induced blockade of HCV replication [20] [21] [22] . In HCV-infected liver samples, more IFN-λ2/3 messenger RNA was detected compared with healthy control livers [23] . Clinical studies with pegylated IFN-λ1 (IL-29) have shown a robust antiviral activity against HCV, and reported a favourable side effect profile as compared with IFN-α [24] , which might be explained by a more tissue-dependent IFN-λ receptor expression compared with IFN-α receptor [25] ; however, the molecular causes of the observed effects of IL28B genetics are still under discussion. The minor allele of rs8099917 has been reported to be associated with lower messenger RNA expression of IL28A/ IL28B [4, 5] ; however, an association attempt between rs12979860 and IL28B RNA expression in peripheral blood mononuclear cells from 80 individuals (HCVnegative population controls) in the SNPExpress database [26] was negative [6] .
The higher frequency of the minor alleles of the three IL28B SNPs in CHC patients compared with healthy controls, and in non-responders to IFN therapy compared with responders, agrees with previous reports. rs12979860 has been associated with spontaneous clearance of HCV [8] . The minor C allele of rs8099917 was more frequent in patients with progression to chronic HCV infection [9] . This SNP was also associated with lower virological response rates to antiviral therapy, with the strongest effects in patients infected with the difficult-to-treat HCV genotypes-1 and -4 [9] . Finally, all three IL28B polymorphisms have been associated with response to pegylated IFN-α and ribavirin therapy in HCV of genotype 1 [4] [5] [6] .
Pyrosequencing™ is a time-and cost-effective genotyping method with high-throughput capability. It is more flexible than other techniques that use preconfigured systems, for example, chip analyses, because assays can be easily added, excluded or modified. In addition, the method is well-suited for everyday SNP analyses of small assay numbers, at equal costs per assay, as with larger samples sizes, because no kit for a predefined number of assays has to be purchased. Compared to 5′ nuclease (TaqMan ® ) assays (another established genotyping technique), the material costs are similar, with costs up to €1.50 per sample (€400 for a TaqMan ® SNP genotyping assay kit sufficient for 300 samples). With both techniques, the genetic diagnosis is available after approximately 4 h; however, the PSQ96™ instrument needs only 15 min per 96-well plate, the limiting step being the 2 h real-time PCR reaction, which opens the possibility of increasing the throughput by making more PCRs available.
The costs and efforts required for the present genotyping might be further reduced when diagnosing only rs12980275, which would provide, with satisfactory certainty, the diagnosis of rs12979860; however, the diagnosis of rs8099917 is only provided with moderate certainty. For the latter, however, screening for rs12979860 would be better, as indicated by a slightly greater k-value. Because rs12980275 showed the best b Please note that to sustain the conventional gene description from the 5′-end to 3′-end, the single nucleotide polymorphism (SNP) denominations were changed from previous publications [4] [5] [6] , that is, rs8099917A>C might be elsewhere named T>G, rs12979860G>A might be named C>T and rs12980275T>C is also named A>G. CI, confidence interval. significances in the present data and the other two SNPs provided no further association information, a single SNP assay might be contemplated with caution; however, from the present data, this can only be proposed for HCV genotype-1 patients and could differ with other viral genotypes. The linkage of the three SNPs also supports such an assay simplification; however, LD was not enough to form a haploblock. In this respect, the present genetic architecture might differ from that recently described as containing a haplotype spanning rs8099917 and rs12979860 [9] . Reasons for different haploblock identifications might be slightly different LDs, to which the various haploblock identification techniques (for example, the herein used 95% confidence intervals on D′ approach [11] being the default in several software programmes, the alternative four gamete rule [27] or the solid spine of the LD method implemented in the HaploView software [28] ) might be differentially vulnerable. The current absence of the haploblock is, therefore, not a substantial contradiction of haplotypes, as long as the LD values are comparable. An exploratory haplotype analysis in the present data provided no additional information to that obtained with the SNPs alone and, considering the absence of haploblock, was, therefore not further investigated. The routine genotyping of patients might improve therapy decision making. This approach enables the dissection of causes directly linked to natural disease defence mechanisms and, thus, provides hints at potential drug targets. The screening for IL28B rs12980275, and rs8099917 and rs12979860 identifies important factors associated with the therapy course of HCV infection.
